|
|
SH4
|
|
|
Osiris Therapeutics, Inc.
|
|
|
IgG1
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension
|
|
|
Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
|
|
|
lymphoblast
|
|
|
Cell Type: hybridoma: B lymphocyte;
|
|
|
immunoglobulin; monoclonal antibody; against human mesenchymal stem cells
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water. To make the complete growth medium, add the following components to the base medium:
-
fetal bovine serum to a final concentration of 20%
-
1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere ATCC tested fetal bovine serum is available as ATCC Catalog No. 30-2020.
Temperature: 37.0°C
|
|
|
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml.
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: Complete growth medium, 92.5%; DMSO, 7.5%
Storage temperature: liquid nitrogen vapor phase
|
|
|
recommended serum:ATCC 30-2020
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 46-X
|
|
|
22086: Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996
49752: Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137
|
